Full Text View
Tabular View
No Study Results Posted
Related Studies
The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
This study has been terminated.
( no eligible patient )
Study NCT00472433   Information provided by Phramongkutklao College of Medicine and Hospital

First Received on April 25, 2007.   Last Updated on June 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Autoimmune Cytopenias
Additional conditions recognized in this trial
Anemia
Leukopenia
Pancytopenia
Thrombocytopenia
More general conditions related to this trial
Blood Platelet Disorders
Hematologic Diseases
Leukocyte Disorders
Interventions listed in this trial
Alemtuzumab
Additional drug interventions recognized in this trial
Antibodies, Neoplasm
Campath 1G
More general drug interventions related to this trial
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Phramongkutklao College of Medicine and Hospital
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services